{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+glargine+U-100", "query": { "intervention": "Insulin glargine U-100" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+glargine+U-100&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T00:12:16.027Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02688933", "title": "A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "HOE901-U300 (Insulin Glargine 300 U/ml)", "type": "DRUG" }, { "name": "Lantus (Insulin Glargine 100 U/ml)", "type": "DRUG" }, { "name": "Mandated back ground therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 638, "start_date": "2016-05-05", "completion_date": "2017-06-19", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-09-02T00:12:16.027Z", "location_count": 99, "location_summary": "Little Rock, Arkansas • Concord, California • Escondido, California + 80 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02688933" }, { "nct_id": "NCT07797335", "title": "AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes", "Cardiovascular Risk" ], "interventions": [ { "name": "Zenagamtide", "type": "DRUG" }, { "name": "Insulin glargine U-100", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 1778, "start_date": "2026-08-24", "completion_date": "2028-09-20", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-02T00:12:16.027Z", "location_count": 109, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Lancaster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07797335" }, { "nct_id": "NCT03013985", "title": "Glargine U300 Hospital Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Glargine U300", "type": "DRUG" }, { "name": "Glargine U100", "type": "DRUG" }, { "name": "Glulisine Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 247, "start_date": "2017-05-17", "completion_date": "2019-03-22", "has_results": true, "last_update_posted_date": "2020-05-07", "last_synced_at": "2026-09-02T00:12:16.027Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013985" }, { "nct_id": "NCT02058160", "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Insulin glargine/lixisenatide (HOE901/AVE0010)", "type": "DRUG" }, { "name": "Insulin glargine (HOE901)", "type": "DRUG" }, { "name": "Metformin (Background Drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 736, "start_date": "2014-01", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-09-02T00:12:16.027Z", "location_count": 108, "location_summary": "Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02058160" }, { "nct_id": "NCT03687827", "title": "A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin degludec", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 498, "start_date": "2018-10-02", "completion_date": "2019-12-27", "has_results": true, "last_update_posted_date": "2021-01-12", "last_synced_at": "2026-09-02T00:12:16.027Z", "location_count": 34, "location_summary": "Chandler, Arizona • Tucson, Arizona • Fresno, California + 28 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03687827" }, { "nct_id": "NCT01499082", "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "HOE901-U300 (new formulation of insulin glargine)", "type": "DRUG" }, { "name": "Lantus (insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 807, "start_date": "2011-12", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2022-03-25", "last_synced_at": "2026-09-02T00:12:16.027Z", "location_count": 95, "location_summary": "Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 78 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01499082" }, { "nct_id": "NCT04537923", "title": "A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Insulin Lispro (U100)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1428, "start_date": "2020-10-19", "completion_date": "2022-11-01", "has_results": true, "last_update_posted_date": "2023-11-02", "last_synced_at": "2026-09-02T00:12:16.027Z", "location_count": 40, "location_summary": "Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04537923" }, { "nct_id": "NCT04484779", "title": "A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 1 Diabetes", "Type 2 Diabetes" ], "interventions": [ { "name": "IIM System", "type": "DEVICE" }, { "name": "Insulin Lispro and/or Insulin Glargine", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2020-07-14", "completion_date": "2020-12-22", "has_results": false, "last_update_posted_date": "2021-01-07", "last_synced_at": "2026-09-02T00:12:16.027Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • Walnut Creek, California • Austin, Texas + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Austin", "state": "Texas" }, { "city": "Round Rock", "state": "Texas" }, { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04484779" }, { "nct_id": "NCT01676220", "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "HOE901-U300 (new formulation of insulin glargine)", "type": "DRUG" }, { "name": "Lantus (insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 878, "start_date": "2012-08", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-09-02T00:12:16.027Z", "location_count": 117, "location_summary": "Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01676220" }, { "nct_id": "NCT03668808", "title": "Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Insulin Degludec", "type": "DRUG" }, { "name": "Insulin Glargine", "type": "DRUG" }, { "name": "TRESIBA® FLEXTOUCH®", "type": "DEVICE" }, { "name": "LANTUS® SOLOSTAR® INSULIN PEN", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sansum Diabetes Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2018-11-16", "completion_date": "2020-09-19", "has_results": true, "last_update_posted_date": "2022-11-01", "last_synced_at": "2026-09-02T00:12:16.027Z", "location_count": 2, "location_summary": "Santa Barbara, California • Honolulu, Hawaii", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT03668808" } ] }